Paul has been with NDA since 2007, focusing on the development and registration of a wide variety of biotherapeutic modalities, ranging from peptides through to genetically modified cellular therapies. He applies a multi-disciplinary, risk-based approach for building effective development strategies from lead candidate selection onwards, with a particular focus on immunogenicity-related considerations.
Paul is a member of Immunogenicity Integrated, this is a platform created by three members of the NDA Advisory Board, who combine extensive multi-disciplinary experience of assessing immunogenicity for different biotherapeutic modalities, including ATMPs. Deeper understanding of intrinsic and extrinsic factors that may influence immunogenicity enables de-risking of the product development process in a manner that is fully aligned with regulatory expectations. NDA group and Immunogenicity Integrated work in close partnership to provide documentation, including risk assessment for Clinical Trial Applications and Scientific Advice meetings, and the Integrated Summary of Immunogenicity for global registration dossiers.
Key Areas Of Expertise
- Identification, evaluation & mitigation of immunogenicity-related risks for biotherapeutic development
- Understanding global regulatory standards for analytical, bioanalytical, clinical methodology and data presentation to enable successful registration
- Building commercial value incrementally via a stage-gate approach
- Advocacy to manage unexpected results
- High-quality dossier preparation, specializing in Immunogenicity Risk Assessment documentation and the Integrated Summary of Immunogenicity.
Before Joining The NDA Advisory Board
Paul was Senior Director, Biopharmaceutical Development Programs, at MDS Pharma Services. Previously, he held various R&D and Regulatory Affairs roles in SmithKline Beecham, Amgen, Metris Therapeutics & Sanofi-Synthélabo.
Wessels H, Lehnick D, Höfler J, Jankowsky R, Chamberlain P & Roth K. Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019 Oct; 7(5): e00507
Chamberlain P., Kurki P. (2018) Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective. In: Gutka H., Yang H., Kakar S. (eds) Biosimilars. AAPS Advances in the Pharmaceutical Sciences Series, vol 34. Springer
Baker, M. P., Jones, T. D. and Chamberlain, P. (2017) Immunogenicity of Biologics, in Protein Therapeutics (eds T. Vaughan, J. Osbourn and B. Jallal), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527699124.ch12
Paul Chamberlain. The role of immunogenicity evaluation for biosimilars. In: Biosimilar Drug Product Development; edited by Laszlo Endrenyi, Paul Jules Declerck & Shein Chung Chow; CRC Press 2017; Pages 361–374
Chamberlain PD. Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years’ experience of the European Union regulatory pathway. Biosimilars 2014, 4, 23-43.